U.S. FDA approves Bayer drug Aliqopa (copanlisib) for follicular lymphoma
Bayer recently won U.S. FDA approval to market its oncology drug Aliqopa (copanlisib) for the treatment of follicular lymphoma.
Company : Bayer
For Treatment of : Follicular lymphoma
Therapeutic Areas : Hematology, Oncology
General Information of Aliqopa (copanlisib)
Aliqopa (copanlisib) is a kinase inhibitor with activity predominantly against the PI3K-alpha and PI3K-delta isoforms expressed in malignant B cells.
Aliqopa is specifically indicated for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.
Aliqopa is supplied as a solution for intravenous infusion. The recommended dose is 60 mg administered as a 1-hour intravenous infusion on Days 1, 8, and 15 of a 28-day treatment cycle on an intermittent schedule (three weeks on and one week off). Continue treatment until disease progression or unacceptable toxicity.